CNSP vs CNTX

CNS Pharmaceuticals, Inc. vs Context Therapeutics Inc. — Valuation Comparison 2026

CNSP

Biotechnology
CNS Pharmaceuticals, Inc.
Quality
3.6
out of 10
Value Trap
39
LOW
Price
$4.89
Last close
Models
7/13
Active
VS

CNTX

Biotechnology
Context Therapeutics Inc.
Quality
4.5
out of 10
Value Trap
18
SAFE
Price
$2.83
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CNSP Fair ValueCNSP Upside CNTX Fair ValueCNTX Upside
Bayesian DCF Intrinsic $2.41 -50.6% $1.08 -61.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.10 -52.2% $0.10 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CNSP vs CNTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CNSP vs CNTX — Which Stock Is More Undervalued?

CNTX scores higher with a 4.5/10 quality rating vs CNSP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CNS Pharmaceuticals, Inc. (CNSP) and Context Therapeutics Inc. (CNTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CNSP currently trades at $4.89 with a QOC of 3.6/10, while CNTX trades at $2.83 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).